CGNX is trading at $66.89 after pulling back from its pre-earnings high of $70.71, with analysts responding to the Q2 print by lifting targets across the board — the question now is whether the Street's revised numbers can pull the stock back toward those levels.
The analyst response to earnings has been uniformly constructive on price targets, even if ratings remain split. Four firms raised their targets on August 7 alone. Needham lifted to $80 from $75 while maintaining Buy. Cantor Fitzgerald went to $84 from $76 on an Overweight. Citigroup moved to $74 from $72 but held at Neutral. Truist raised to $78 from $71 on a Hold. The pattern is telling: bulls are getting more bullish, but the cautious camp isn't budging on ratings. The consensus mean target now sits at $80.58, roughly 20% above current levels — a gap wide enough to be meaningful, close enough to be credible given the stock traded near $71 just days ago.
Positioning is notably relaxed for a stock that just moved through earnings. Short interest dipped fractionally on the week — down less than 0.3% — to 4.4% of the free float, continuing the broader unwind from the early-July peak near 5.1%. The borrow market is loose: availability runs at roughly 1,000%, meaning lenders hold about ten shares for every one currently borrowed. Cost to borrow has crept up about 15% over the week to 0.52%, but in absolute terms that remains trivially cheap. Options tell a slightly more guarded story — the put/call ratio has edged up to 0.31 from a recent low around 0.20 in early July, about 0.7 standard deviations above the 20-day mean. That is not a defensive extreme; it looks more like routine post-earnings normalisation than a fear trade.
The forward earnings picture is the clearest bull argument. EPS momentum over a 90-day window ranks in the 76th percentile. More strikingly, the 12-month forward EPS growth estimate ranks in the 98th percentile across the universe — the earnings revision cycle has been strongly positive. Bulls frame Cognex as the default beneficiary of any manufacturing automation upcycle, with machine vision leadership and optionality from M&A. Bears counter that the valuation demands execution: the stock trades at 40.5x trailing earnings and 32x EV/EBITDA, with little room for a miss. The EV/EBITDA multiple has compressed about 2.4 points over the past 30 days, reflecting the price pullback rather than a fundamental re-rating — the earnings bar just got higher with each raised target.
Among closely correlated peers, the week looked constructive for the group broadly. IPGP gained 6.1% on the week and BDC added 7.1%, while LFUS and CTS each gained around 3%. CGNX's 2.5% weekly gain trails the peer median, which makes sense given it absorbed the earnings event itself. The relative underperformance is modest and consistent with a stock digesting a 22% pre-earnings run rather than signalling a shift in sentiment.
The ORTEX short score has edged up slightly to 40.8 — the highest reading in the current 10-day window, though still within a narrow range and well below levels that would flag elevated short-side conviction. Insider activity is dated to May and consisted of routine VP and principal accounting officer sales at prices near current levels, adding little fresh signal.
The next earnings date is November 6. Between now and then, the key variable is whether the revised Street targets — clustered between $74 and $84 — attract fresh institutional demand at current prices, or whether the post-earnings gap fill between $67 and $71 becomes a ceiling rather than a floor.
See the live data behind this article on ORTEX.
Open CGNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
